Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Entrada Therapeutics has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2024.
Entrada Therapeutics's investors include Janus Henderson Investors, TCG Crossover, Wellington Management, Goldman Sachs, Redmile Group.
Entrada Therapeutics is headquartered in Boston, United States.
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Entrada Therapeutics is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Entrada Therapeutics — Funding & Investors." VCBacked, June 24, 2024, https://www.vcbacked.co/company/entrada-therapeutics. Accessed November 13, 2026.
VCBacked. (2024). Entrada Therapeutics — Funding & Investors. Retrieved November 13, 2026, from https://www.vcbacked.co/company/entrada-therapeutics
{{cite web |title=Entrada Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/entrada-therapeutics |website=VCBacked |access-date=November 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Entrada Therapeutics? Request a listing update